Journals

NCATS: Getting Insights Through the Risky "Middle Zone" to Drug Development
Evidence-Based Oncology > June 2019
Mary Caffrey
Addressing Oncologists' Gaps in the Use of Biosimilar Products
Evidence-Based Oncology > June 2019
Chad Williamson, MBA, MS; Leanne Berger, BS, Thomas P. Sullivan, BS; Jeffrey Crawford, MD; and Gary H. Lyman, MD, MPH, FASCO, FRCP
From the Editor-in-Chief: New Ways to Pay for Cures
Evidence-Based Oncology > June 2019
Joseph Alvarnas, MD
NCCN's Putnam Serving as Point of Contact for Payers, Employers to Keep Cancer Care "Accessible"
Evidence-Based Oncology > June 2019
Mary Caffrey
Two-Sided Risk in the Oncology Care Model
Evidence-Based Oncology > June 2019
Kashyap Patel, MD, ABOIM, BCMAS; Maharshi Patel, MBA; Taylor Lavender, BS, PA; Dhwani Mehta, MS, RD; Asutosh Gor, MD, Sashi Naidu, MD; and Chuck Newton, BS
MIT Group Brings Together Stakeholders to Brainstorm How to Pay for Curative Therapies Over Time
Evidence-Based Oncology > June 2019
Mary Caffrey
Editor’s Letter: Dennis P. Scanlon, PhD
The American Journal of Accountable Care > June 2019
Dennis P. Scanlon, PhD
Participating Faculty
Supplements > Assessing the Burden of Illness of Chronic Hepatitis C and Impact of Direct-Acting Antiviral Use on Healthcare Costs in Medicaid
Assessing the Burden of Illness of Chronic Hepatitis C and the Impact of Direct-Acting Antiviral Use on Healthcare Costs in Medicaid
Supplements > Assessing the Burden of Illness of Chronic Hepatitis C and Impact of Direct-Acting Antiviral Use on Healthcare Costs in Medicaid
M. Christopher Roebuck, PhD; Joshua N. Liberman, PhD
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.